The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

Have a sex or relationship question? Ask Rachel about it using the form below or email [email protected] ...

Ozempic has always come with side effects. The latest reported by users? Thinning hair and muscle loss. Experts break down ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

President Donald Trump's new European tariffs may spell bad news for Novo Nordisk, maker of Ozempic and Wegovy. As Axios ...

WEIGHT loss jabs could raise the risk of sudden blindness, a study warns. Injections like Wegovy, Mounjaro and Ozempic are ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some success ...

Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

Government programs may soon change how they approach a growing public health challenge that affects millions of Americans each year.

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach ...